PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.

MLA

Koerner, Julia, et al. “PLGA-Particle Vaccine Carrying TLR3/RIG-I Ligand Riboxxim Synergizes with Immune Checkpoint Blockade for Effective Anti-Cancer Immunotherapy.” Nature Communications, vol. 12, no. 1, May 2021, pp. 1–16. EBSCOhost, https://doi.org/10.1038/s41467-021-23244-3.

APA

Koerner, J., Horvath, D., Herrmann, V. L., MacKerracher, A., Gander, B., Yagita, H., Rohayem, J., & Groettrup, M. (2021). PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nature Communications, 12(1), 1–16. https://doi.org/10.1038/s41467-021-23244-3

Chicago

Koerner, Julia, Dennis Horvath, Valerie L. Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, and Marcus Groettrup. 2021. “PLGA-Particle Vaccine Carrying TLR3/RIG-I Ligand Riboxxim Synergizes with Immune Checkpoint Blockade for Effective Anti-Cancer Immunotherapy.” Nature Communications 12 (1): 1–16. doi:10.1038/s41467-021-23244-3.